Entellus Medical (ENTL)Posts Q3 Loss of 32c/Share; Updates FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Entellus Medical Announces Third Quarter 2015 Financial Results
November 5, 2015 4:07 PM ESTPLYMOUTH, Minn., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended September 30, 2015.
Recent Highlights and Accomplishments
Revenues of $14.8 million in the third quarter of 2015, an increase of 27% versus the third quarter of 2014 Achieved balanced revenue growth across ENT offices and OR's In-Office revenues represented 58% of total XprESS product revenue in the third... More


